Recently, the “2024 Recommended Catalog of Innovative Products Application Demonstration in Hubei Province”, which was evaluated and approved by Hubei Provincial Department of Economy and Informatization, Hubei Provincial Department of Science and Technology, Hubei Provincial Development and Reform Commission and other ten units, was announced, and “Human AGTR1, ACE, ADRB1, CYP2D6, CYP2C9 Gene Detection Kit (PCR-Fluorescent Probe Method)”, which was independently researched, developed and produced by Wuhan YZY Medical Science and Technology Co. The “Human AGTR1, ACE, ADRB1, CYP2D6, CYP2C9 Gene Detection Kit (PCR-Fluorescent Probe Method)” was successfully selected.
The selection of the Recommended Catalog of Innovative Products Application Demonstration in Hubei Province is aimed at promoting the application demonstration of innovative products, facilitating the innovative development of enterprises, and promoting the transformation and upgrading of industries. The innovative products selected for the Catalog are developed and produced through original innovation, integrated innovation and digestion, absorption and re-innovation, which are in line with the national industrial policy, advanced, novel and practical, and at the same time have high market potential and wide promotion value.
About the product
Hypertension is a major factor in the incidence of stroke and coronary heart disease and death in our population, and the prevalence of hypertension in China has shown a significant upward trend over the past 50 years. For the treatment of hypertension, multiple antihypertensive drugs are usually taken simultaneously in order to achieve better antihypertensive effects. The choice of which antihypertensive mechanism of drugs can reduce the side effects of hypertension drugs at the same time, but also improve the effectiveness of medication, has been of great concern to the clinic. Clinical practice has revealed that the response of different patients to the same antihypertensive drugs varies individually, and genetic polymorphism is an important factor influencing the individualization of drug response.
YZY Med Entry Kit is suitable for the qualitative detection of AGTR1, ACE, ADRB1, CYP2D6 and CYP2C9 gene polymorphisms in DNA of human venous whole blood samples, which can assist in guiding the individualized dosing of hypertension medications including β-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin II receptor antagonists (ARBs). The product has the advantages of higher throughput, open reagents, simple interpretation, anti-contamination system, and lower limit of detection as low as 0.5ng/μL.
The selection marks that our products have been fully recognized by the government and customers in terms of technological advancement, promotion value and market potential.
About YZY Med
As a high-tech enterprise specializing in the research, development, production and sales of individualized medical diagnostic products, YZY Med has independently developed and produced molecular diagnostic products to guide the individualized medication for cardiovascular and cerebrovascular diseases, concomitant diagnostic products to guide the diagnosis and treatment of tumors, fluorescence in-situ hybridization products, as well as circulating tumor cell assay products, which provide the basis for clinical diagnosis in the field of precision medicine. The company will take the opportunity of being selected in the Catalog to continuously increase independent innovation, uphold a responsible attitude towards the industry, establish an industry benchmark with high-quality products, and continue to help the high-speed and high-quality development of precision medicine.
